[go: up one dir, main page]

CY1120681T1 - Υγρη φαρμακευτικη συνθεση - Google Patents

Υγρη φαρμακευτικη συνθεση

Info

Publication number
CY1120681T1
CY1120681T1 CY181100952T CY181100952T CY1120681T1 CY 1120681 T1 CY1120681 T1 CY 1120681T1 CY 181100952 T CY181100952 T CY 181100952T CY 181100952 T CY181100952 T CY 181100952T CY 1120681 T1 CY1120681 T1 CY 1120681T1
Authority
CY
Cyprus
Prior art keywords
adalimumab
acetic acid
pharmaceutical composition
ingredients
liquid pharmaceutical
Prior art date
Application number
CY181100952T
Other languages
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Rio Alessandra Del
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120681(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of CY1120681T1 publication Critical patent/CY1120681T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέες υγρές φαρμακευτικές συνθέσεις αδαλιμουμάμπης, οι οποίες περιλαμβάνουν αδαλιμουμάμπη ή ένα βιοομοειδές αυτής, έναν ρυθμιστικό παράγοντα/σύστημα οξικού οξέος όπως οξικό νάτριο/οξικό οξύ και έναν σταθεροποιητή σακχάρου όπως η τρεαλόζη. Ένας τέτοιος συνδυασμός συστατικών παρέχει σκευάσματα που έχουν σταθερότητα (π.χ. κατά την αποθήκευση και την έκθεση σε καταπόνηση), η οποία είναι συγκρίσιμη ή βελτιωμένη με όσα είναι γνωστά στην τεχνική, και λιγότερα συστατικά. Τέτοιες πρόοδοι συμβάλλουν στο να γίνουν οι θεραπείες της αδαλιμουμάμπης ευρέως διαθέσιμες με χαμηλότερο κόστος και να παρατείνουν τη βιωσιμότητα των προ-φορτωμένων συσκευών χορήγησης (πχ. προγεμισμένες σύριγγες) για τη μείωση των περισσευμάτων φαρμάκου.
CY181100952T 2014-05-23 2018-09-14 Υγρη φαρμακευτικη συνθεση CY1120681T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169753.2A EP2946765B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition
PCT/EP2015/060816 WO2015177057A1 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
CY1120681T1 true CY1120681T1 (el) 2019-12-11

Family

ID=50774704

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100952T CY1120681T1 (el) 2014-05-23 2018-09-14 Υγρη φαρμακευτικη συνθεση

Country Status (25)

Country Link
US (7) US10426832B2 (el)
EP (4) EP3050557A1 (el)
JP (1) JP6334819B2 (el)
KR (4) KR20210108504A (el)
CN (2) CN109248315B (el)
AU (3) AU2015263340B2 (el)
BR (2) BR112016026879A8 (el)
CA (2) CA2946953C (el)
CY (1) CY1120681T1 (el)
DK (2) DK2946765T3 (el)
ES (3) ES2600488T3 (el)
HR (2) HRP20161311T1 (el)
HU (2) HUE029849T2 (el)
IL (3) IL249115B (el)
LT (2) LT2946765T (el)
MX (1) MX361061B (el)
NZ (1) NZ725360A (el)
PL (2) PL2946765T3 (el)
PT (2) PT2946765T (el)
RS (2) RS55548B1 (el)
RU (2) RU2719431C2 (el)
SG (3) SG10202000517YA (el)
SI (2) SI2946765T1 (el)
SM (1) SMT201800454T1 (el)
WO (1) WO2015177057A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
SI2946765T1 (sl) 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
MA45562B1 (fr) * 2016-06-30 2024-05-31 Celltrion Inc Préparation pharmaceutique liquide stable
MA47106A (fr) * 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
EP3569224B1 (en) * 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula
IT201700004019A1 (it) * 2017-01-16 2018-07-16 Gk Pharma Consultans Sa Composizione comprendente carnitina, colato di sodio, acetato di sodio ed eventualmente argento per uso nel trattamento di psoriasi, vitiligine e rosacea
UA123847C2 (uk) * 2017-03-16 2021-06-09 Лг Кем, Лтд. Рідка композиція анти-tnf альфа антитіла
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
US20210070850A1 (en) * 2017-09-20 2021-03-11 Alvotech Hf Pharmaceutical formulations for adalimumab
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
AU2020207124A1 (en) * 2019-01-11 2021-07-29 Samsung Bioepis Co., Ltd. Pharmaceutical composition comprising antibody, device comprising same, and use thereof
AU2020364480A1 (en) * 2019-10-08 2022-03-31 Samsung Bioepis Co., Ltd. Stable liquid composition, method for preparing same, and formulation comprising same
WO2022235882A1 (en) * 2021-05-05 2022-11-10 I2O Therapeutics, Inc. Ionic liquid formulations for treating inflammatory and autoimmune diseases
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ536216A (en) 1996-02-09 2006-08-31 Abbott Biotech Ltd Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2006012500A2 (en) 2004-07-23 2006-02-02 Genentech, Inc. Crystallization of antibodies or fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2007010971A (es) 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
RS52861B (en) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF (ALPHA)
AU2008334099B2 (en) 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP3011953A1 (en) 2008-10-29 2016-04-27 Ablynx N.V. Stabilised formulations of single domain antigen binding molecules
JP2012509270A (ja) 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
JP5937523B2 (ja) 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN103124564B (zh) 2010-03-22 2016-11-09 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012065072A2 (en) 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
BR112013033671B1 (pt) 2011-07-01 2022-10-18 Biogen Ma Inc Composições de polipeptídeo de fusão fc livre de arginina e uso
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP3412310B1 (en) 2012-03-07 2022-09-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
KR20150070384A (ko) 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
CA2889488A1 (en) 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US10688187B2 (en) * 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
SI2946765T1 (sl) 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) * 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP3569224B1 (en) 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula

Also Published As

Publication number Publication date
US11707524B2 (en) 2023-07-25
MX2016015304A (es) 2017-02-22
JP6334819B2 (ja) 2018-05-30
PL3145487T3 (pl) 2018-11-30
US20210121566A1 (en) 2021-04-29
AU2015263340B2 (en) 2018-08-09
US20200016268A1 (en) 2020-01-16
KR20200017553A (ko) 2020-02-18
DK2946765T3 (en) 2016-10-31
KR102296766B1 (ko) 2021-09-03
BR122021022508B1 (pt) 2023-04-11
IL282481A (en) 2021-06-30
ES2971213T3 (es) 2024-06-04
CA3073703A1 (en) 2015-11-26
US20210322551A1 (en) 2021-10-21
US10426832B2 (en) 2019-10-01
JP2017516846A (ja) 2017-06-22
PT3145487T (pt) 2018-10-19
RS55548B1 (sr) 2017-05-31
WO2015177057A1 (en) 2015-11-26
RU2016150640A3 (el) 2018-12-07
US20170196974A1 (en) 2017-07-13
EP3050557A1 (en) 2016-08-03
SG10202000517YA (en) 2020-03-30
KR20170005864A (ko) 2017-01-16
AU2020203119A1 (en) 2020-05-28
MX361061B (es) 2018-11-23
PT2946765T (pt) 2016-11-10
EP2946765B1 (en) 2016-08-31
IL263473A (en) 2019-01-31
EP3476386B1 (en) 2024-01-24
RU2016150640A (ru) 2018-06-26
KR20210108504A (ko) 2021-09-02
RU2719431C2 (ru) 2020-04-17
BR112016026879A2 (pt) 2017-08-15
HUE029849T2 (en) 2017-04-28
HRP20161311T1 (hr) 2016-12-02
CN106456538A (zh) 2017-02-22
LT3145487T (lt) 2018-09-25
EP3145487A1 (en) 2017-03-29
ES2600488T3 (es) 2017-02-09
HRP20181479T1 (hr) 2018-11-02
BR112016026879A8 (pt) 2021-06-29
ES2687600T3 (es) 2018-10-26
EP3476386A1 (en) 2019-05-01
US10729769B2 (en) 2020-08-04
US20210308262A1 (en) 2021-10-07
CA2946953A1 (en) 2015-11-26
CN109248315B (zh) 2021-11-09
IL249115B (en) 2018-12-31
RS57780B1 (sr) 2018-12-31
HUE040237T2 (hu) 2019-02-28
IL263473B (en) 2021-05-31
SMT201800454T1 (it) 2018-11-09
PL2946765T3 (pl) 2017-08-31
US20210030871A1 (en) 2021-02-04
AU2015263340A1 (en) 2016-11-03
RU2020112952A (ru) 2020-06-03
SI2946765T1 (sl) 2016-11-30
SG11201608745QA (en) 2016-11-29
CN109248315A (zh) 2019-01-22
EP3476386C0 (en) 2024-01-24
NZ725360A (en) 2019-09-27
SI3145487T1 (sl) 2018-10-30
KR20230004960A (ko) 2023-01-06
IL249115A0 (en) 2017-01-31
DK3145487T3 (en) 2018-10-01
US20210196824A1 (en) 2021-07-01
SG10201806300VA (en) 2018-08-30
CA2946953C (en) 2021-05-18
AU2018220051B2 (en) 2020-06-04
LT2946765T (lt) 2016-11-25
EP2946765A1 (en) 2015-11-25
AU2018220051A1 (en) 2018-09-06
US11712471B2 (en) 2023-08-01
EP3145487B1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
CY1120681T1 (el) Υγρη φαρμακευτικη συνθεση
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
EA202090124A1 (ru) Аденовирус, вооруженный биспецифическим рекрутером t-клеток (bite)
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX2021012050A (es) Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
EA201792047A1 (ru) Новые соединения
EA201791733A1 (ru) Производные 9h-пирролодипиридина
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
CY1123195T1 (el) Ενεσιμη φαρμακοτεχνiκη μορφη
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом